Insider transactions

EDGAR

DBV Technologies S.A

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-22.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
5 transactions, 3,370,091 shares
Sum of shares × price per share: 15,487,991.21

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–9 of 9

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-07-29 Filed 2026-07-31Mohideen Pharis Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)4642.70
1,252.8

Derived: shares × price per share. Exact value 1252.80.

144,531Direct (D) No
F1, F2, F3
  • F1 The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares.
  • F2 Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
  • F3 This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1380 to EURO 1.00 as of July 29, 2026.
Open filing 0001760395-26-000008 Read from the filing’s XML Dispute this row
2026-01-29 Filed 2026-02-02Mohideen Pharis Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)5344.86
2,595.24

Derived: shares × price per share. Exact value 2595.24.

144,995Direct (D) No
F1, F2, F3
  • F1 The ordinary shares may be represented by American Depositary Shares, each of which currently represents five ordinary shares.
  • F2 Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
  • F3 This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1974 to EURO 1.00 as of January 29, 2026.
Open filing 0001760395-26-000002 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-14BAKER BROS. ADVISORS LP DirectorBaker Bros. Advisors (GP) LLC Director667, L.P. DirectorBaker Brothers Life Sciences LP DirectorBAKER FELIX DirectorBAKER JULIAN Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: BS Warrant — underlying Second Pre-Funded Warrant (2,299,656)
Disposed (D)2,299,6560—0Indirect (I) See FootnotesNo
F1, F2, F7, F8, F9, F3, F4, F5
  • F1 On January 12, 2026, 667, L.P. (667) and Baker Brothers Life Sciences, L.P. (Life Sciences and together with 667, the Funds) exercised, respectively, 2,299,656 and 25,005,240 warrants (each, a BS Warrant) of DBV Technologies S.A. (the Issuer), at a strike price of EUR 1.5764, on a one-for-one basis into pre-funded warrants (each, a Second Pre-Funded Warrant), each of which are exercisable for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR 0.0175.
  • F2 The BS Warrants were exercisable until January 15, 2026, which is 30 days following the publication by the Issuer that the VITESSE Phase 3 study met its primary endpoint as further described in the Terms and Conditions of the BS Warrants.
  • F7 Each Second Pre-Funded Warrant is exercisable initially for 1.75 Ordinary Shares per Second Pre-Funded Warrant. The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a Second Pre-Funded Warrant Share) of EUR 0.01. The Second Pre-Funded Warrants may be exercised until April 7, 2035. (continued in Note 8)
  • F8 (continued from Note 7) The Second Pre-Funded Warrants are only exercisable to the extent that immediately prior to or after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 9.99% of the Issuer's outstanding Ordinary Shares (the Second Pre-Funded Warrant Beneficial Ownership Limitation). A holder, upon notice to the Issuer, may increase or decrease the Second Pre-Funded Warrant Beneficial Ownership Limitation, provided that (a) to the extent required by law, in cases of the Second Pre-Funded Warrant Beneficial Ownership Limitation being increased above 9.99%, the holder has obtained certain French regulatory approvals as described in the Terms and Conditions of the Second Pre-Funded Warrants and (continued in Note 9)
  • F9 (continued from Note 9) (b) the Second Pre-Funded Warrant Beneficial Ownership Limitation in no event exceeds 19.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder, and with respect to the French FDI Regime (as defined in the Terms and Conditions of the Second Pre-Funded Warrants), does not exceed 24.99% of the voting rights immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder. Any increase in the Second Pre-funded Warrant Beneficial Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer.
  • F3 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  • F4 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the Adviser GP) is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
  • F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
Open filing 0001193125-26-012991 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-14BAKER BROS. ADVISORS LP DirectorBaker Bros. Advisors (GP) LLC Director667, L.P. DirectorBaker Brothers Life Sciences LP DirectorBAKER FELIX DirectorBAKER JULIAN Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: BS Warrant — underlying Second Pre-Funded Warrant (25,005,240)
Disposed (D)25,005,2400—0Indirect (I) See FootnotesNo
F1, F2, F7, F8, F9, F4, F5, F6
  • F1 On January 12, 2026, 667, L.P. (667) and Baker Brothers Life Sciences, L.P. (Life Sciences and together with 667, the Funds) exercised, respectively, 2,299,656 and 25,005,240 warrants (each, a BS Warrant) of DBV Technologies S.A. (the Issuer), at a strike price of EUR 1.5764, on a one-for-one basis into pre-funded warrants (each, a Second Pre-Funded Warrant), each of which are exercisable for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR 0.0175.
  • F2 The BS Warrants were exercisable until January 15, 2026, which is 30 days following the publication by the Issuer that the VITESSE Phase 3 study met its primary endpoint as further described in the Terms and Conditions of the BS Warrants.
  • F7 Each Second Pre-Funded Warrant is exercisable initially for 1.75 Ordinary Shares per Second Pre-Funded Warrant. The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a Second Pre-Funded Warrant Share) of EUR 0.01. The Second Pre-Funded Warrants may be exercised until April 7, 2035. (continued in Note 8)
  • F8 (continued from Note 7) The Second Pre-Funded Warrants are only exercisable to the extent that immediately prior to or after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 9.99% of the Issuer's outstanding Ordinary Shares (the Second Pre-Funded Warrant Beneficial Ownership Limitation). A holder, upon notice to the Issuer, may increase or decrease the Second Pre-Funded Warrant Beneficial Ownership Limitation, provided that (a) to the extent required by law, in cases of the Second Pre-Funded Warrant Beneficial Ownership Limitation being increased above 9.99%, the holder has obtained certain French regulatory approvals as described in the Terms and Conditions of the Second Pre-Funded Warrants and (continued in Note 9)
  • F9 (continued from Note 9) (b) the Second Pre-Funded Warrant Beneficial Ownership Limitation in no event exceeds 19.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder, and with respect to the French FDI Regime (as defined in the Terms and Conditions of the Second Pre-Funded Warrants), does not exceed 24.99% of the voting rights immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder. Any increase in the Second Pre-funded Warrant Beneficial Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer.
  • F4 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the Adviser GP) is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
  • F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  • F6 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
Open filing 0001193125-26-012991 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-14BAKER BROS. ADVISORS LP DirectorBaker Bros. Advisors (GP) LLC Director667, L.P. DirectorBaker Brothers Life Sciences LP DirectorBAKER FELIX DirectorBAKER JULIAN Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Second Pre-Funded Warrant — underlying Ordinary Shares (4,024,398)
Acquired (A)2,299,6560—2,299,656Indirect (I) See FootnotesNo
F1, F7, F8, F9, F3, F4, F5
  • F1 On January 12, 2026, 667, L.P. (667) and Baker Brothers Life Sciences, L.P. (Life Sciences and together with 667, the Funds) exercised, respectively, 2,299,656 and 25,005,240 warrants (each, a BS Warrant) of DBV Technologies S.A. (the Issuer), at a strike price of EUR 1.5764, on a one-for-one basis into pre-funded warrants (each, a Second Pre-Funded Warrant), each of which are exercisable for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR 0.0175.
  • F7 Each Second Pre-Funded Warrant is exercisable initially for 1.75 Ordinary Shares per Second Pre-Funded Warrant. The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a Second Pre-Funded Warrant Share) of EUR 0.01. The Second Pre-Funded Warrants may be exercised until April 7, 2035. (continued in Note 8)
  • F8 (continued from Note 7) The Second Pre-Funded Warrants are only exercisable to the extent that immediately prior to or after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 9.99% of the Issuer's outstanding Ordinary Shares (the Second Pre-Funded Warrant Beneficial Ownership Limitation). A holder, upon notice to the Issuer, may increase or decrease the Second Pre-Funded Warrant Beneficial Ownership Limitation, provided that (a) to the extent required by law, in cases of the Second Pre-Funded Warrant Beneficial Ownership Limitation being increased above 9.99%, the holder has obtained certain French regulatory approvals as described in the Terms and Conditions of the Second Pre-Funded Warrants and (continued in Note 9)
  • F9 (continued from Note 9) (b) the Second Pre-Funded Warrant Beneficial Ownership Limitation in no event exceeds 19.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder, and with respect to the French FDI Regime (as defined in the Terms and Conditions of the Second Pre-Funded Warrants), does not exceed 24.99% of the voting rights immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder. Any increase in the Second Pre-funded Warrant Beneficial Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer.
  • F3 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  • F4 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the Adviser GP) is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
  • F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
Open filing 0001193125-26-012991 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-01-14BAKER BROS. ADVISORS LP DirectorBaker Bros. Advisors (GP) LLC Director667, L.P. DirectorBaker Brothers Life Sciences LP DirectorBAKER FELIX DirectorBAKER JULIAN Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Second Pre-Funded Warrant — underlying Ordinary Shares (43,759,170)
Acquired (A)25,005,2400—25,005,240Indirect (I) See FootnotesNo
F1, F7, F8, F9, F4, F5, F6
  • F1 On January 12, 2026, 667, L.P. (667) and Baker Brothers Life Sciences, L.P. (Life Sciences and together with 667, the Funds) exercised, respectively, 2,299,656 and 25,005,240 warrants (each, a BS Warrant) of DBV Technologies S.A. (the Issuer), at a strike price of EUR 1.5764, on a one-for-one basis into pre-funded warrants (each, a Second Pre-Funded Warrant), each of which are exercisable for 1.75 Ordinary Shares of the Issuer at an exercise price of EUR 0.0175.
  • F7 Each Second Pre-Funded Warrant is exercisable initially for 1.75 Ordinary Shares per Second Pre-Funded Warrant. The Second Pre-Funded Warrants bear an unpaid exercise price per Ordinary Share issuable pursuant to such Second Pre-Funded Warrants (a Second Pre-Funded Warrant Share) of EUR 0.01. The Second Pre-Funded Warrants may be exercised until April 7, 2035. (continued in Note 8)
  • F8 (continued from Note 7) The Second Pre-Funded Warrants are only exercisable to the extent that immediately prior to or after giving effect to such exercise the holders thereof, their affiliates and any persons who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 9.99% of the Issuer's outstanding Ordinary Shares (the Second Pre-Funded Warrant Beneficial Ownership Limitation). A holder, upon notice to the Issuer, may increase or decrease the Second Pre-Funded Warrant Beneficial Ownership Limitation, provided that (a) to the extent required by law, in cases of the Second Pre-Funded Warrant Beneficial Ownership Limitation being increased above 9.99%, the holder has obtained certain French regulatory approvals as described in the Terms and Conditions of the Second Pre-Funded Warrants and (continued in Note 9)
  • F9 (continued from Note 9) (b) the Second Pre-Funded Warrant Beneficial Ownership Limitation in no event exceeds 19.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder, and with respect to the French FDI Regime (as defined in the Terms and Conditions of the Second Pre-Funded Warrants), does not exceed 24.99% of the voting rights immediately after giving effect to the issuance of shares upon exercise of the Second Pre-Funded Warrants held by the holder. Any increase in the Second Pre-funded Warrant Beneficial Ownership Limitation will not be effective until the sixty-first (61st) day after such notice is delivered to the Issuer.
  • F4 Baker Bros. Advisors LP (the Adviser) serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the Adviser GP) is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
  • F5 Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  • F6 After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the securities reported in column 9 of Table II held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
Open filing 0001193125-26-012991 Read from the filing’s XML Dispute this row
2025-12-18 Filed 2025-12-19EPIC Bpifrance Other: Member of 10% owner groupBpifrance Participations SA Other: Member of 10% owner groupBpifrance SA Other: Member of 10% owner groupBpifrance Investissement S.A.S. Other: Member of 10% owner groupCAISSE DES DEPOTS ET CONSIGNATIONS Other: Member of 10% owner group
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)1,292,1034.19
5,413,911.57

Derived: shares × price per share. Exact value 5413911.57.

7,303,369Indirect (I) By Bpifrance Participations S.A.No
F4, F2
  • F4 The price reported in Column 4 is a weighted average price in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1727 to EURO 1.00 as of December 18, 2025 . The shares were sold in multiple transactions at prices ranging from $3.79 to $4.32 per share, inclusive.
  • F2 Bpifrance Participations S.A. (Bpifrance Participations) directly owns the reported shares. Bpifrance Participations is a subsidiary owned at 99.99% by Bpifrance S.A. (Bpifrance). Bpifrance is jointly owned by Caisse des Depots et Consignations (CDC) at 49.2% and EPIC Bpifrance (EPIC) at 49.2%. CDC and EPIC jointly control Bpifrance.
Open filing 0001104659-25-123104 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19EPIC Bpifrance Other: Member of 10% owner groupBpifrance Participations SA Other: Member of 10% owner groupBpifrance SA Other: Member of 10% owner groupBpifrance Investissement S.A.S. Other: Member of 10% owner groupCAISSE DES DEPOTS ET CONSIGNATIONS Other: Member of 10% owner group
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)2,036,9904.84
9,859,031.6

Derived: shares × price per share. Exact value 9859031.60.

8,635,472Indirect (I) By Bpifrance Participations S.A.No
F1, F2
  • F1 The price reported in Column 4 is a weighted average price in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1741 to EURO 1.00 as of December 17, 2025. The shares were sold in multiple transactions at prices ranging from $4.24 to $5.23 per share, inclusive. The reporting person unterakes to provide DBV Technologies S.A., any security holder of DBV Technologies S.A., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 4 of this Form 4.
  • F2 Bpifrance Participations S.A. (Bpifrance Participations) directly owns the reported shares. Bpifrance Participations is a subsidiary owned at 99.99% by Bpifrance S.A. (Bpifrance). Bpifrance is jointly owned by Caisse des Depots et Consignations (CDC) at 49.2% and EPIC Bpifrance (EPIC) at 49.2%. CDC and EPIC jointly control Bpifrance.
Open filing 0001104659-25-123104 Read from the filing’s XML Dispute this row
2025-12-17 Filed 2025-12-19EPIC Bpifrance Other: Member of 10% owner groupBpifrance Participations SA Other: Member of 10% owner groupBpifrance SA Other: Member of 10% owner groupBpifrance Investissement S.A.S. Other: Member of 10% owner groupCAISSE DES DEPOTS ET CONSIGNATIONS Other: Member of 10% owner group
S

Open market or private sale of non-derivative or derivative security

Ordinary Shares
Disposed (D)40,0005.28
211,200

Derived: shares × price per share. Exact value 211200.00.

8,595,472Indirect (I) By Bpifrance Participations S.A.No
F3, F2
  • F3 The price reported in Column 4 reflects the conversion of EURO to USD at an exchange rate of $1.1741 to EURO 1.00 as of December 17, 2025.
  • F2 Bpifrance Participations S.A. (Bpifrance Participations) directly owns the reported shares. Bpifrance Participations is a subsidiary owned at 99.99% by Bpifrance S.A. (Bpifrance). Bpifrance is jointly owned by Caisse des Depots et Consignations (CDC) at 49.2% and EPIC Bpifrance (EPIC) at 49.2%. CDC and EPIC jointly control Bpifrance.
Open filing 0001104659-25-123104 Read from the filing’s XML Dispute this row

Latest reported holdings

What each reporting owner last said they hold, as of the date shown. A transaction not yet filed is not in it.

Latest reported holdings
Reporting ownerSecurityShares owned afterDirect or indirectSource
667, L.P. DirectorBS Warrant Derivative security · underlying Second Pre-Funded Warrant0I See FootnotesAs of 2026-01-12 Open filing 4
667, L.P. Director · 10% ownerFirst Pre-Funded Warrant Derivative security · underlying Ordinary Shares25,005,240I See FootnotesAs of 2025-03-27 Open filing 4
667, L.P. DirectorSecond Pre-Funded Warrant Derivative security · underlying Ordinary Shares25,005,240I See FootnotesAs of 2026-01-12 Open filing 4
BAKER BROS. ADVISORS LP DirectorBS Warrant Derivative security · underlying Second Pre-Funded Warrant0I See FootnotesAs of 2026-01-12 Open filing 4
BAKER BROS. ADVISORS LP Director · 10% ownerFirst Pre-Funded Warrant Derivative security · underlying Ordinary Shares25,005,240I See FootnotesAs of 2025-03-27 Open filing 4
BAKER BROS. ADVISORS LP DirectorSecond Pre-Funded Warrant Derivative security · underlying Ordinary Shares25,005,240I See FootnotesAs of 2026-01-12 Open filing 4
BAKER FELIX DirectorBS Warrant Derivative security · underlying Second Pre-Funded Warrant0I See FootnotesAs of 2026-01-12 Open filing 4
BAKER FELIX Director · 10% ownerFirst Pre-Funded Warrant Derivative security · underlying Ordinary Shares25,005,240I See FootnotesAs of 2025-03-27 Open filing 4
BAKER FELIX DirectorSecond Pre-Funded Warrant Derivative security · underlying Ordinary Shares25,005,240I See FootnotesAs of 2026-01-12 Open filing 4
BAKER JULIAN DirectorBS Warrant Derivative security · underlying Second Pre-Funded Warrant0I See FootnotesAs of 2026-01-12 Open filing 4
BAKER JULIAN Director · 10% ownerFirst Pre-Funded Warrant Derivative security · underlying Ordinary Shares25,005,240I See FootnotesAs of 2025-03-27 Open filing 4
BAKER JULIAN DirectorSecond Pre-Funded Warrant Derivative security · underlying Ordinary Shares25,005,240I See FootnotesAs of 2026-01-12 Open filing 4
Baker Bros. Advisors (GP) LLC DirectorBS Warrant Derivative security · underlying Second Pre-Funded Warrant0I See FootnotesAs of 2026-01-12 Open filing 4
Baker Bros. Advisors (GP) LLC Director · 10% ownerFirst Pre-Funded Warrant Derivative security · underlying Ordinary Shares25,005,240I See FootnotesAs of 2025-03-27 Open filing 4
Baker Bros. Advisors (GP) LLC DirectorSecond Pre-Funded Warrant Derivative security · underlying Ordinary Shares25,005,240I See FootnotesAs of 2026-01-12 Open filing 4
Baker Brothers Life Sciences LP DirectorBS Warrant Derivative security · underlying Second Pre-Funded Warrant0I See FootnotesAs of 2026-01-12 Open filing 4
Baker Brothers Life Sciences LP Director · 10% ownerFirst Pre-Funded Warrant Derivative security · underlying Ordinary Shares25,005,240I See FootnotesAs of 2025-03-27 Open filing 4
Baker Brothers Life Sciences LP DirectorSecond Pre-Funded Warrant Derivative security · underlying Ordinary Shares25,005,240I See FootnotesAs of 2026-01-12 Open filing 4
Boucinha Virginie Officer: Chief Financial OfficerEmployee Stock Option (right to buy) Derivative security · underlying Ordinary Shares192,000D As of 2025-11-21 Open filing 4
Boucinha Virginie Officer: Chief Financial OfficerOrdinary Shares 70,000D As of 2025-11-21 Open filing 4
Bpifrance Investissement S.A.S. Other: Member of 10% owner groupOrdinary Shares 226,133I By Innobio FPCIAs of 2025-12-19 Open filing 4
Bpifrance Investissement S.A.S. Other: Member of 10% owner groupOrdinary Shares 7,303,369I By Bpifrance Participations S.A.As of 2025-12-18 Open filing 4
Bpifrance Participations SA 10% ownerOrdinary Shares 10,672,462I By Bpifrance Participations S.A.As of 2025-04-07 Open filing 3
Bpifrance Participations SA Other: Member of 10% owner groupOrdinary Shares 226,133I By Innobio FPCIAs of 2025-12-19 Open filing 4
Bpifrance Participations SA Other: Member of 10% owner groupOrdinary Shares 7,303,369I By Bpifrance Participations S.A.As of 2025-12-18 Open filing 4
Bpifrance SA 10% ownerOrdinary Shares 10,672,462I By Bpifrance Participations S.A.As of 2025-04-07 Open filing 3
Bpifrance SA Other: Member of 10% owner groupOrdinary Shares 226,133I By Innobio FPCIAs of 2025-12-19 Open filing 4
Bpifrance SA Other: Member of 10% owner groupOrdinary Shares 7,303,369I By Bpifrance Participations S.A.As of 2025-12-18 Open filing 4
CAISSE DES DEPOTS ET CONSIGNATIONS 10% ownerOrdinary Shares 10,672,462I By Bpifrance Participations S.A.As of 2025-04-07 Open filing 3
CAISSE DES DEPOTS ET CONSIGNATIONS Other: Member of 10% owner groupOrdinary Shares 226,133I By Innobio FPCIAs of 2025-12-19 Open filing 4
CAISSE DES DEPOTS ET CONSIGNATIONS Other: Member of 10% owner groupOrdinary Shares 7,303,369I By Bpifrance Participations S.A.As of 2025-12-18 Open filing 4
EPIC Bpifrance Other: Member of 10% owner groupOrdinary Shares 10,672,462I By Bpifrance Participations S.A.As of 2025-05-20 Open filing 3
EPIC Bpifrance Other: Member of 10% owner groupOrdinary Shares 226,133I By Innobio FPCIAs of 2025-12-19 Open filing 4
EPIC Bpifrance Other: Member of 10% owner groupOrdinary Shares 7,303,369I By Bpifrance Participations S.A.As of 2025-12-18 Open filing 4
Mohideen Pharis Officer: Chief Medical OfficerEmployee Stock Option (right to buy) Derivative security · underlying Ordinary Shares253,000D As of 2025-11-21 Open filing 4
Mohideen Pharis Officer: Chief Medical OfficerOrdinary Shares 144,531D As of 2026-07-29 Open filing 4
Tasse Daniel Director · Officer: CHIEF EXECUTIVE OFFICEREmployee Stock Option (right to buy) Derivative security · underlying Ordinary Shares964,000D As of 2025-11-21 Open filing 4
Trapp Kevin Michael Officer: Chief Commercial OfficerEmployee Stock Option (right to buy) Derivative security · underlying Ordinary Shares316,250D As of 2025-11-21 Open filing 4
Trapp Kevin Michael Officer: Chief Commercial OfficerOrdinary Shares 55,000D As of 2025-11-21 Open filing 4

Joint filers each report the same shares, so rows are not added together.

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–50 of 66

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
RA CAPITAL MANAGEMENT, L.P. 3,657,644 SH43,013,893 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-128411 Filed 2026-11-16 Dispute this row
MPM BIOIMPACT LLC 3,044,659 SH35,805,190 dollarsLower by 621,625 Prior quarter: 3,666,284Open filing 0001193125-26-463462 Filed 2026-11-16 Dispute this row
Siren, L.L.C. Partly reported under another manager2,356,539 SH27,712,899 dollarsHigher by 499,177 Prior quarter: 1,857,362Open filing 0002005245-26-000013 Filed 2026-11-12 Dispute this row
ADAR1 Capital Management, LLC 2,010,831 SH23,647,373 dollarsHigher by 1,482,536 Prior quarter: 528,295Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row
Vivo Capital, LLC 1,844,758 SH21,694,354 dollarsUnchanged Prior quarter: 1,844,758Open filing 0001213900-26-119459 Filed 2026-11-13 Dispute this row
Artisan Partners Limited Partnership 1,584,020 SH18,628,075 dollarsHigher by 211,169 Prior quarter: 1,372,851Open filing 0001466153-26-000009 Filed 2026-11-13 Dispute this row
BAKER BROS. ADVISORS LP 1,461,425 SH17,186,358 dollarsUnchanged Prior quarter: 1,461,425Open filing 0001104659-26-128308 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager1,435,282 SH16,878,917 dollarsHigher by 121,843 Prior quarter: 1,313,439Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
PERCEPTIVE ADVISORS LLC 1,136,534 SH13,365,640 dollarsLower by 516,816 Prior quarter: 1,653,350Open filing 0001012975-26-001063 Filed 2026-11-16 Dispute this row
Patient Square Capital LP 1,105,606 SH13,001,927 dollarsHigher by 196,132 Prior quarter: 909,474Open filing 0001819257-26-000007 Filed 2026-11-10 Dispute this row
Octagon Capital Advisors LP 574,200 SH6,752,592 dollarsUnchanged Prior quarter: 574,200Open filing 0001839435-26-000006 Filed 2026-11-16 Dispute this row
MILLENNIUM MANAGEMENT LLC 552,991 SH6,503,174 dollarsHigher by 285,208 Prior quarter: 267,783Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
Ikarian Capital, LLC 453,374 SH1,065,356 dollarsLower by 71,626 Prior quarter: 525,000Open filing 0001420506-26-002881 Filed 2026-11-16 Dispute this row
FMR LLC Partly reported under another manager428,800 SH5,042,688 dollarsNot in the prior quarter’s filings read Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
AMERIPRISE FINANCIAL INC Partly reported under another manager415,466 SH4,885,881 dollarsHigher by 36,969 Prior quarter: 378,497Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row
Redmile Group, LLC 373,417 SH4,391,384 dollarsLower by 37,023 Prior quarter: 410,440Open filing 0000905148-26-004923 Filed 2026-11-16 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager276,134 SH3,247,336 dollarsHigher by 253,352 Prior quarter: 22,782Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
Ishara Investments LP 270,000 SH3,175,200 dollarsHigher by 85,500 Prior quarter: 184,500Open filing 0002111609-26-000005 Filed 2026-11-16 Dispute this row
Elmind Capital, LP 265,000 SH3,116,400 dollarsUnchanged Prior quarter: 265,000Open filing 0001013594-26-001197 Filed 2026-11-16 Dispute this row
GREAT POINT PARTNERS LLC Partly reported under another manager250,000 SH2,940,000 dollarsHigher by 93,094 Prior quarter: 156,906Open filing 0001172661-26-005345 Filed 2026-11-16 Dispute this row
JANE STREET GROUP, LLC Partly reported under another manager185,410 SH2,180,422 dollarsLower by 38,505 Prior quarter: 223,915Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
Duquesne Family Office LLC 173,028 SH2,035 dollarsLower by 210,335 Prior quarter: 383,363Open filing 0001536411-26-000011 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager171,622 SH2,018,274 dollarsLower by 783,286 Prior quarter: 954,908Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
Yiheng Capital Management, L.P. 170,142 SH2,000,870 dollarsUnchanged Prior quarter: 170,142Open filing 0001420506-26-002824 Filed 2026-11-16 Dispute this row
BOOTHBAY FUND MANAGEMENT, LLC 141,703 SH1,666,427 dollarsLower by 21,698 Prior quarter: 163,401Open filing 0001549230-26-000012 Filed 2026-11-16 Dispute this row
Russell Investments Group, Ltd. Partly reported under another manager80,917 SH951,583 dollarsLower by 3,279 Prior quarter: 84,196Open filing 0001193125-26-451241 Filed 2026-11-06 Dispute this row
Polymer Capital Management (HK) LTD 64,500 SH758,520 dollarsUnchanged Prior quarter: 64,500Open filing 0001970465-26-000010 Filed 2026-11-13 Dispute this row
DEUTSCHE BANK AG\ Partly reported under another manager59,240 SH696,662 dollarsUnchanged Prior quarter: 59,240Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row
Qube Research Technologies Ltd 48,158 SH566,338 dollarsHigher by 19,353 Prior quarter: 28,805Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row
TWO SIGMA INVESTMENTS, LP 44,552 SH523,932 dollarsHigher by 32,922 Prior quarter: 11,630Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row
WELLS FARGO COMPANY/MN Partly reported under another manager37,500 SH441,000 dollarsHigher by 37,200 Prior quarter: 300Open filing 0000072971-26-000342 Filed 2026-11-16 Dispute this row
ENVESTNET ASSET MANAGEMENT INC 30,831 SH362,573 dollarsLower by 82,992 Prior quarter: 113,823Open filing 0001214659-26-014231 Filed 2026-11-16 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Call Partly reported under another manager30,100 SH353,976 dollarsNot in the prior quarter’s filings read Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
XTX Topco Ltd Partly reported under another manager26,517 SH311,840 dollarsLower by 64,685 Prior quarter: 91,202Open filing 0001828301-26-000009 Filed 2026-11-16 Dispute this row
HRT FINANCIAL LP 25,492 SH299 dollarsLower by 125,705 Prior quarter: 151,197Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row
Cetera Investment Advisers 22,918 SH269,516 dollarsLower by 12,339 Prior quarter: 35,257Open filing 0001666741-26-000005 Filed 2026-11-13 Dispute this row
China Universal Asset Management Co., Ltd. 21,600 SH249,480 dollarsHigher by 13,600 Prior quarter: 8,000Open filing 0001906594-26-000005 Filed 2026-10-28 Dispute this row
Persistent Asset Partners Ltd 18,902 SH222,288 dollarsHigher by 3,272 Prior quarter: 15,630Open filing 0002056052-26-000005 Filed 2026-11-13 Dispute this row
Engineers Gate Manager LP 14,200 SH166,992 dollarsLower by 18,239 Prior quarter: 32,439Open filing 0001620220-26-000010 Filed 2026-11-16 Dispute this row
SEI INVESTMENTS CO Partly reported under another manager13,326 SH156,719 dollarsHigher by 2,517 Prior quarter: 10,809Open filing 0000350894-26-000059 Filed 2026-11-10 Dispute this row
Vontobel Holding Ltd. Partly reported under another manager12,248 SH144,036 dollarsNot in the prior quarter’s filings read Open filing 0001588340-26-000004 Filed 2026-10-16 Dispute this row
CITADEL ADVISORS LLC Option: Call Partly reported under another manager10,100 SH118,776 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
RHUMBLINE ADVISERS 5,366 SH63,097 dollarsLower by 245 Prior quarter: 5,611Open filing 0001115418-26-000015 Filed 2026-11-10 Dispute this row
BARCLAYS PLC Partly reported under another manager4,784 SH56,260 dollarsLower by 2,414 Prior quarter: 7,198Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
GAMMA Investing LLC Partly reported under another manager2,607 SH30,658 dollarsLower by 225 Prior quarter: 2,832Open filing 0002010235-26-000007 Filed 2026-10-08 Dispute this row
Allworth Financial LP 1,683 SH19,793 dollarsUnchanged Prior quarter: 1,683Open filing 0001140361-26-044466 Filed 2026-11-17 Dispute this row
State of Wyoming 957 SH11,254 dollarsLower by 488 Prior quarter: 1,445Open filing 0001821626-26-000009 Filed 2026-10-28 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager907 SH10,476 dollarsHigher by 854 Prior quarter: 53Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager837 SH9,843 dollarsNot in the prior quarter’s filings read Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
Continuum Advisory, LLC 400 SH4,704 dollarsUnchanged Prior quarter: 400Open filing 0001420506-26-002682 Filed 2026-11-13 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Logos Global Management LP 915,000 SH
  • NEW YORK STATE COMMON RETIREMENT FUND 119,335 SH
  • Diversify Advisory Services, LLC 89,692 SH
  • DIVERSIFY WEALTH MANAGEMENT, LLC 89,692 SH
  • Dorsey Wright Associates 73,115 SH
  • LPL Financial LLC 53,751 SH
  • AdvisorShares Investments LLC 43,663 SH
  • STIFEL FINANCIAL CORP 27,608 SH
  • Burns Matteson Capital Management, LLC 21,818 SH
  • Atria Investments, Inc 18,902 SH
  • PERSONAL CFO SOLUTIONS, LLC 12,940 SH
  • Point72 Asset Management, L.P. 12,148 SH
  • GEODE CAPITAL MANAGEMENT, LLC 11,574 SH
  • Integrated Wealth Concepts LLC 10,369 SH
  • Optiver Holding B.V. 6,455 SH
  • BERTHEL, FISHER COMPANY FINANCIAL SERVICES, INC. 6,349 SH
  • Truvestments Capital LLC 3,892 SH
  • Rockefeller Capital Management L.P. 1,246 SH
  • HM PAYSON CO 420 SH
  • Ascentis Wealth Management, LLC 259 SH
  • NISA INVESTMENT ADVISORS, LLC 200 SH
  • Farther Finance Advisors, LLC 164 SH
  • Stone House Investment Management, LLC 9 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text; they are read only when their rows add up to the totals the filer states.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Institutional ownership reported on Form 13F

13F filers report holding between 5.97% and 7.91% of shares outstanding.

Quarter ending 2026-09-30, against 314,388,807 shares on the cover dated 2026-10-26.

  • The lower figure counts positions a manager reports as its own with sole discretion. The upper figure counts every plain-share position and can count a share twice.
  • Neither includes holders that do not file Form 13F, or managers below the filing threshold.
Quarter-by-quarter 13F holders
QuarterManagers holdingShares, at leastShares, at mostFilings read
2026-09-30 6418,779,50924,878,4618,935
2026-06-30 8015,605,48421,540,5919,178
2026-03-31 7317,754,50421,190,3439,173
2025-12-31 5213,260,45916,176,0969,222
2025-09-30 336,069,0506,519,3088,469
2025-06-30 306,642,4917,232,6418,516
2025-03-31 182,121,9252,467,9628,518
2024-12-31 192,152,9802,737,0858,580

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read from their tags. Earlier schedules are free text: they are read only when every cover page states a share count and a percent, and the rest are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
MPM BioImpact LLC Ordinary Shares, nominal value 0.10 euro per share4.815,223,295.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 3Open filing 0001687078-26-000024 Dispute this row
Invus Public Equities, L.P. Ordinary Shares, nominal value Euro 0.10 per share7.323,095,116.0009/30/2026 Filed 2026-11-12SCHEDULE 13G/AAmendment 3Open filing 0002005369-26-000058 Dispute this row
Invus Public Equities Advisors, LLC Ordinary Shares, nominal value Euro 0.10 per share7.323,095,116.0009/30/2026 Filed 2026-11-12SCHEDULE 13G/AAmendment 3Open filing 0002005369-26-000058 Dispute this row
Invus Global Management, LLC Ordinary Shares, nominal value Euro 0.10 per share7.323,095,116.0009/30/2026 Filed 2026-11-12SCHEDULE 13G/AAmendment 3Open filing 0002005369-26-000058 Dispute this row
Siren, L.L.C. Ordinary Shares, nominal value Euro 0.10 per share7.323,095,116.0009/30/2026 Filed 2026-11-12SCHEDULE 13G/AAmendment 3Open filing 0002005369-26-000058 Dispute this row
Avicenna Life Sci Master Fund LP Ordinary Shares, nominal value Euro 0.10 per share0.51,621,060.0009/30/2026 Filed 2026-11-12SCHEDULE 13G/AAmendment 3Open filing 0002005369-26-000058 Dispute this row
Avicenna Life Sci Master GP LLC Ordinary Shares, nominal value Euro 0.10 per share0.51,621,060.0009/30/2026 Filed 2026-11-12SCHEDULE 13G/AAmendment 3Open filing 0002005369-26-000058 Dispute this row
Ulys, L.L.C. Ordinary Shares, nominal value Euro 0.10 per share0.51,621,060.0009/30/2026 Filed 2026-11-12SCHEDULE 13G/AAmendment 3Open filing 0002005369-26-000058 Dispute this row
Raymond Debbane Ordinary Shares, nominal value Euro 0.10 per share7.924,716,176.0009/30/2026 Filed 2026-11-12SCHEDULE 13G/AAmendment 3Open filing 0002005369-26-000058 Dispute this row
RA Capital Management, L.P. Ordinary shares, nominal value EUR 0.10 per share5.818,288,220.0007/30/2026 Filed 2026-08-06SCHEDULE 13GOpen filing 0001346824-26-000213 Dispute this row
Peter Kolchinsky Ordinary shares, nominal value EUR 0.10 per share5.818,288,220.0007/30/2026 Filed 2026-08-06SCHEDULE 13GOpen filing 0001346824-26-000213 Dispute this row
Rajeev Shah Ordinary shares, nominal value EUR 0.10 per share5.818,288,220.0007/30/2026 Filed 2026-08-06SCHEDULE 13GOpen filing 0001346824-26-000213 Dispute this row
RA Capital Healthcare Fund, L.P. Ordinary shares, nominal value EUR 0.10 per share5.818,288,220.0007/30/2026 Filed 2026-08-06SCHEDULE 13GOpen filing 0001346824-26-000213 Dispute this row
MPM BioImpact LLC Ordinary Shares, nominal value 0.10 euro per share6.218,331,420.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001687078-26-000019 Dispute this row
MPM BioImpact LLC Ordinary Shares, nominal value 0.10 euro per share8.826,066,806.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0001687078-26-000012 Dispute this row
Artisan Partners Asset Management Inc. American Depositary Shares3.72,219,38603/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-220564 Dispute this row
Artisan Partners Holdings LP American Depositary Shares3.72,219,38603/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-220564 Dispute this row
Artisan Investments GP LLC American Depositary Shares3.72,219,38603/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-220564 Dispute this row
Artisan Partners Limited Partnership American Depositary Shares3.72,219,38603/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-220564 Dispute this row
Adage Capital Management, L.P. Ordinary Shares, nominal value 0.10 euro per share7.3122,272,884.0003/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-002909 Dispute this row
Robert Atchinson Ordinary Shares, nominal value 0.10 euro per share7.3122,272,884.0003/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-002909 Dispute this row
Phillip Gross Ordinary Shares, nominal value 0.10 euro per share7.3122,272,884.0003/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0000919574-26-002909 Dispute this row
Vivo Opportunity Fund Holdings, L.P. Ordinary shares, nominal value 0.10 euro per share, represented by American Depository Shares4.011,820,005.0003/31/2026 Filed 2026-05-12SCHEDULE 13G/AAmendment 2Open filing 0001213900-26-055373 Dispute this row
Vivo Opportunity, LLC Ordinary shares, nominal value 0.10 euro per share, represented by American Depository Shares4.011,820,005.0003/31/2026 Filed 2026-05-12SCHEDULE 13G/AAmendment 2Open filing 0001213900-26-055373 Dispute this row
Vivo Opportunity Cayman Fund, L.P. Ordinary shares, nominal value 0.10 euro per share, represented by American Depository Shares0.51,517,840.0003/31/2026 Filed 2026-05-12SCHEDULE 13G/AAmendment 2Open filing 0001213900-26-055373 Dispute this row
Vivo Opportunity Cayman, LLC Ordinary shares, nominal value 0.10 euro per share, represented by American Depository Shares0.51,517,840.0003/31/2026 Filed 2026-05-12SCHEDULE 13G/AAmendment 2Open filing 0001213900-26-055373 Dispute this row
Invus Public Equities, L.P. Ordinary Shares, nominal value Euro 0.10 per share6.117,997,870.0003/31/2026 Filed 2026-05-05SCHEDULE 13G/AAmendment 2Open filing 0002005369-26-000033 Dispute this row
Invus Public Equities Advisors, LLC Ordinary Shares, nominal value Euro 0.10 per share6.117,997,870.0003/31/2026 Filed 2026-05-05SCHEDULE 13G/AAmendment 2Open filing 0002005369-26-000033 Dispute this row
Invus Global Management, LLC Ordinary Shares, nominal value Euro 0.10 per share6.117,997,870.0003/31/2026 Filed 2026-05-05SCHEDULE 13G/AAmendment 2Open filing 0002005369-26-000033 Dispute this row
Siren, L.L.C. Ordinary Shares, nominal value Euro 0.10 per share6.117,997,870.0003/31/2026 Filed 2026-05-05SCHEDULE 13G/AAmendment 2Open filing 0002005369-26-000033 Dispute this row
Avicenna Life Sci Master Fund LP Ordinary Shares, nominal value Euro 0.10 per share0.41,312,135.0003/31/2026 Filed 2026-05-05SCHEDULE 13G/AAmendment 2Open filing 0002005369-26-000033 Dispute this row
Avicenna Life Sci Master GP LLC Ordinary Shares, nominal value Euro 0.10 per share0.41,312,135.0003/31/2026 Filed 2026-05-05SCHEDULE 13G/AAmendment 2Open filing 0002005369-26-000033 Dispute this row
Ulys, L.L.C. Ordinary Shares, nominal value Euro 0.10 per share0.41,312,135.0003/31/2026 Filed 2026-05-05SCHEDULE 13G/AAmendment 2Open filing 0002005369-26-000033 Dispute this row
Raymond Debbane Ordinary Shares, nominal value Euro 0.10 per share6.519,310,005.0003/31/2026 Filed 2026-05-05SCHEDULE 13G/AAmendment 2Open filing 0002005369-26-000033 Dispute this row
Vivo Opportunity Fund Holdings, L.P. Ordinary shares, nominal value 0.10 euro per share, presented by American Depository Shares5.715,685,950.0001/12/2026 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-016649 Dispute this row
Vivo Opportunity, LLC Ordinary shares, nominal value 0.10 euro per share, presented by American Depository Shares5.715,685,950.0001/12/2026 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-016649 Dispute this row
Vivo Opportunity Cayman Fund, L.P. Ordinary shares, nominal value 0.10 euro per share, presented by American Depository Shares0.72,014,280.0001/12/2026 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-016649 Dispute this row
Vivo Opportunity Cayman, LLC Ordinary shares, nominal value 0.10 euro per share, presented by American Depository Shares0.72,014,280.0001/12/2026 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-016649 Dispute this row
Baker Bros. Advisors LP Ordinary shares, nominal value 0.10 euro per share9.9925,586,190.0001/12/2026 Filed 2026-01-14SCHEDULE 13D/AAmendment 9Open filing 0001104659-26-003806 Dispute this row
Baker Bros. Advisors (GP) LLC Ordinary shares, nominal value 0.10 euro per share9.9925,586,190.0001/12/2026 Filed 2026-01-14SCHEDULE 13D/AAmendment 9Open filing 0001104659-26-003806 Dispute this row
Julian C. Baker Ordinary shares, nominal value 0.10 euro per share9.9925,586,190.0001/12/2026 Filed 2026-01-14SCHEDULE 13D/AAmendment 9Open filing 0001104659-26-003806 Dispute this row
Felix J. Baker Ordinary shares, nominal value 0.10 euro per share9.9925,586,190.0001/12/2026 Filed 2026-01-14SCHEDULE 13D/AAmendment 9Open filing 0001104659-26-003806 Dispute this row
Bpifrance Participations S.A. Ordinary Shares, nominal value EUR0.10 per share4.610,672,462.0001/05/2026 Filed 2026-01-07SCHEDULE 13D/AAmendment 10Open filing 0001104659-26-001744 Dispute this row
Innobio FPCI Ordinary Shares, nominal value EUR0.10 per share0.1226,133.0001/05/2026 Filed 2026-01-07SCHEDULE 13D/AAmendment 10Open filing 0001104659-26-001744 Dispute this row
Bpifrance Investissement SAS Ordinary Shares, nominal value EUR0.10 per share0.1226,133.0001/05/2026 Filed 2026-01-07SCHEDULE 13D/AAmendment 10Open filing 0001104659-26-001744 Dispute this row
Caisse des Depots Ordinary Shares, nominal value EUR0.10 per share4.710,898,595.0001/05/2026 Filed 2026-01-07SCHEDULE 13D/AAmendment 10Open filing 0001104659-26-001744 Dispute this row
EPIC Bpifrance Ordinary Shares, nominal value EUR0.10 per share4.710,898,595.0001/05/2026 Filed 2026-01-07SCHEDULE 13D/AAmendment 10Open filing 0001104659-26-001744 Dispute this row
Bpifrance S.A. Ordinary Shares, nominal value EUR0.10 per share4.710,898,595.0001/05/2026 Filed 2026-01-07SCHEDULE 13D/AAmendment 10Open filing 0001104659-26-001744 Dispute this row
Citadel Advisors LLC Ordinary shares, nominal value EUR0.10 per share (the "Shares")3.17,413,959.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-016493 Dispute this row
Citadel Advisors Holdings LP Ordinary shares, nominal value EUR0.10 per share (the "Shares")3.17,413,959.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-016493 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

3,104,499 filings read, dated 1980-01-02 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015258,595
2016246,472
2017244,814
2018245,575
2019238,619
2020249,093
2021274,850
2022257,922
2023253,676
2024261,106
2025235,525
2026263,830

Filings made before the SEC required XML are listed, not extracted.

Back to DBV Technologies S.A